Tarsus scores first FDA approval for treatment of red, itchy eyes caused by mites
Tarsus Pharmaceuticals has secured the FDA’s first approval to treat irritated eyes caused by tiny mites, a condition known as demodex blepharitis.
The drug, to be marketed as Xdemvy, is an eye drop formulation of the common veterinary drug lotaliner used to prevent tick and flea infestations. Tarsus’ approval came a month before its anticipated decision date, and also marks a first for the small California biotech launched in 2017 with a focus on eye care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.